Cargando…
Rhabdomyosarcomatous Transformation of a Gastrointestinal Stromal Tumor following Treatment with Imatinib
Rhabdomyosarcomatous dedifferentiation of GIST following tyrosine kinase inhibitor (TKI) therapy is rare, with only a handful of cases previously reported in the literature. Herein we present a case of metastatic GIST initially treated with imatinib that developed radiographic evidence of progressio...
Autores principales: | Jiang, Xiaoyin, Anderson, H. Bryan, Guy, Cynthia D., Mosca, Paul J., Riedel, Richard F., Cardona, Diana M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324915/ https://www.ncbi.nlm.nih.gov/pubmed/25694839 http://dx.doi.org/10.1155/2015/317493 |
Ejemplares similares
-
Case report of rhabdomyosarcomatous transformation of a primary gastrointestinal stromal tumor (GIST)
por: Li, Li, et al.
Publicado: (2019) -
Gastrointestinal Stromal Tumor With Chondrosarcomatous Dedifferentiation Following Imatinib Therapy
por: Koufopoulos, Nektarios, et al.
Publicado: (2021) -
Imatinib rechallenge in patients with advanced gastrointestinal
stromal tumors following progression with imatinib, sunitinib and
regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018) -
Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
por: Quek, Richard, et al.
Publicado: (2010) -
Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008)